ProQR Therapeutics BV (PRQR) - Total Assets
Based on the latest financial reports, ProQR Therapeutics BV (PRQR) holds total assets worth $133.50 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ProQR Therapeutics BV - Total Assets Trend (2012–2025)
This chart illustrates how ProQR Therapeutics BV's total assets have evolved over time, based on quarterly financial data. Also see market cap of ProQR Therapeutics BV for the company's overall valuation and market capitalisation.
ProQR Therapeutics BV - Asset Composition Analysis
Current Asset Composition (December 2025)
ProQR Therapeutics BV's total assets of $133.50 Million consist of 88.8% current assets and 11.2% non-current assets. Review how much debt does ProQR Therapeutics BV carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 82.0% |
| Accounts Receivable | $5.97 Million | 4.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how ProQR Therapeutics BV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See PRQR stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ProQR Therapeutics BV's current assets represent 88.8% of total assets in 2025, an increase from 88.5% in 2012.
- Cash Position: Cash and equivalents constituted 82.0% of total assets in 2025, up from 73.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 11.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 4.5% of total assets.
ProQR Therapeutics BV Competitors by Total Assets
Key competitors of ProQR Therapeutics BV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
ProQR Therapeutics BV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.49 | 3.76 | 5.10 |
| Quick Ratio | 3.49 | 3.76 | 5.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $86.72 Million | $107.04 Million | $165.00 Million |
ProQR Therapeutics BV - Advanced Valuation Insights
This section examines the relationship between ProQR Therapeutics BV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.12 |
| Latest Market Cap to Assets Ratio | 2.01 |
| Asset Growth Rate (YoY) | -23.9% |
| Total Assets | $132.43 Million |
| Market Capitalization | $266.71 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values ProQR Therapeutics BV's assets at a significant premium (2.01x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: ProQR Therapeutics BV's assets decreased by 23.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ProQR Therapeutics BV (2012–2025)
The table below shows the annual total assets of ProQR Therapeutics BV from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $132.43 Million | -23.86% |
| 2024-12-31 | $173.92 Million | +14.19% |
| 2023-12-31 | $152.31 Million | -16.70% |
| 2022-12-31 | $182.84 Million | -23.28% |
| 2021-12-31 | $238.33 Million | +97.30% |
| 2020-12-31 | $120.80 Million | -8.44% |
| 2019-12-31 | $131.93 Million | +19.69% |
| 2018-12-31 | $110.23 Million | +72.87% |
| 2017-12-31 | $63.77 Million | -7.76% |
| 2016-12-31 | $69.13 Million | -36.43% |
| 2015-12-31 | $108.75 Million | -22.02% |
| 2014-12-31 | $139.45 Million | +2146.99% |
| 2013-12-31 | $6.21 Million | +1292.73% |
| 2012-12-31 | $445.62K | -- |
About ProQR Therapeutics BV
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic disea… Read more